- $34.93m
- $9.99m
- $4.01m
Brief: Diffusion Pharmaceuticals Stockholders Approve Merger With Eip Pharma
Brief: EIP Pharma And Diffusion Pharmaceuticals Announce Merger Agreement For CNS-Focused Company Treating Neurodegenerative Diseases
Brief: Diffusion Pharmaceuticals Announces Agreement With Lifesci Special Opportunities
Brief: Diffusion Pharmaceuticals Sends Letter To Stockholders
Brief: Lifesci Special Opportunities Nominated Slate Of Director Candidates For Election At Diffusion's Upcoming Annual Meeting
Diffusion Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results, Provides Business Update
Brief: Diffusion Pharmaceuticals Sees Significant Progress In Its Strategic Review Process
Brief: Diffusion Pharmaceuticals Inc Said On November 13 That Board Resolved To Reduce Number Of Directors On Board From Seven To Six
Diffusion Pharmaceuticals Inc expected to post a loss of $2.06 a share - Earnings Preview
Brief: Diffusion Pharma Announces Strategic Review Process To Evaluate Value-Enhancing Alternatives Including Opportunities To Better Leverage TSC
Diffusion Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Diffusion Pharmaceuticals Reports Second Quarter Net Loss Per Share $2.06
Brief: Diffusion Pharmaceuticals To Initiate Phase 2 Trial In Patients With Glioblastoma Multiforme Incorporating Innovative Imaging Methodology To Evaluate Tumor Oxygenation
Brief: Diffusion Pharmaceuticals Says Entered Sales Agreement Under Which Co May Sell Up To $20 Million Shares
Brief: Diffusion Announces Positive Effects In Altitude Trial
Diffusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Diffusion Pharmaceuticals Inc expected to post a loss of $2.00 a share - Earnings Preview
Brief: Diffusion Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements